BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts
Pharmaceutical Science Advances · 2026-12 · 4 · 100128
DOI: 10.1016/j.pscia.2026.100128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Yuhuai Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China.
- BrightGene Bio-Medical Technology Co., Ltd., Suzhou, Jiangsu, 215123, PR China.
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Wang, Y., Xia, J., Ding, H., & Li, D. (2026). BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts. Pharmaceutical Science Advances, 4, 100128. https://doi.org/10.1016/j.pscia.2026.100128
Vancouver
Wang Y, Xia J, Ding H, Li D. BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts. Pharmaceutical Science Advances. 2026;4:100128. doi:10.1016/j.pscia.2026.100128
BibTeX
@article{Wang2026,
author = {Wang, Yuhuai and Xia, Jiahui and Ding, Haifeng and Li, Duxin},
title = {BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100128},
doi = {10.1016/j.pscia.2026.100128}
}
EUVIMED